JP2012021028A5 - - Google Patents

Download PDF

Info

Publication number
JP2012021028A5
JP2012021028A5 JP2011223318A JP2011223318A JP2012021028A5 JP 2012021028 A5 JP2012021028 A5 JP 2012021028A5 JP 2011223318 A JP2011223318 A JP 2011223318A JP 2011223318 A JP2011223318 A JP 2011223318A JP 2012021028 A5 JP2012021028 A5 JP 2012021028A5
Authority
JP
Japan
Prior art keywords
immunotherapeutic agent
composition according
adjuvant
allogeneic
atcc crl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011223318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012021028A (ja
Filing date
Publication date
Priority claimed from GBGB9827104.2A external-priority patent/GB9827104D0/en
Application filed filed Critical
Publication of JP2012021028A publication Critical patent/JP2012021028A/ja
Publication of JP2012021028A5 publication Critical patent/JP2012021028A5/ja
Pending legal-status Critical Current

Links

JP2011223318A 1998-12-10 2011-10-07 ガンの新規処置 Pending JP2012021028A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9827104.2 1998-12-10
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000586359A Division JP4949554B2 (ja) 1998-12-10 1999-12-09 ガンの新規処置

Publications (2)

Publication Number Publication Date
JP2012021028A JP2012021028A (ja) 2012-02-02
JP2012021028A5 true JP2012021028A5 (enExample) 2012-05-17

Family

ID=10843926

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000586359A Expired - Fee Related JP4949554B2 (ja) 1998-12-10 1999-12-09 ガンの新規処置
JP2011223318A Pending JP2012021028A (ja) 1998-12-10 2011-10-07 ガンの新規処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000586359A Expired - Fee Related JP4949554B2 (ja) 1998-12-10 1999-12-09 ガンの新規処置

Country Status (19)

Country Link
US (3) US6972128B1 (enExample)
EP (1) EP1137422B1 (enExample)
JP (2) JP4949554B2 (enExample)
KR (1) KR20010090874A (enExample)
AT (1) ATE304365T1 (enExample)
AU (1) AU763485B2 (enExample)
CA (1) CA2354045C (enExample)
CZ (1) CZ300499B6 (enExample)
DE (1) DE69927286T2 (enExample)
ES (1) ES2249046T3 (enExample)
GB (1) GB9827104D0 (enExample)
HU (1) HUP0104568A3 (enExample)
IL (2) IL143296A0 (enExample)
MX (1) MXPA01005816A (enExample)
NO (1) NO327044B1 (enExample)
NZ (1) NZ512004A (enExample)
PL (1) PL201016B1 (enExample)
WO (1) WO2000033869A2 (enExample)
ZA (1) ZA200104164B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
WO2000071156A2 (en) * 1999-05-21 2000-11-30 Onyvax Limited New vaccine formulations-3
CA2404388C (en) * 2000-04-01 2010-06-15 Onyvax Limited New prostate cell lines
US6667479B2 (en) * 2001-06-01 2003-12-23 Raytheon Company Advanced high speed, multi-level uncooled bolometer and method for fabricating same
US20050019336A1 (en) * 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
MXPA06002159A (es) * 2003-08-26 2006-05-22 Becton Dickinson Co Metodos para la administracion intradermica de agentes terapeuticos.
EP2127671B1 (en) * 2007-02-07 2016-09-14 Nec Corporation Therapeutic agent for cancer
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
AU2009200767A1 (en) * 2008-03-10 2009-09-24 Aristocrat Technologies Australia Pty Limited A gaming system and a method of gaming
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
AU2370195A (en) * 1994-04-28 1995-11-29 Scott Freeman Cell lines obtained by (in vivo) migration and by fusion with autoimmune cells
US5837233A (en) * 1995-03-17 1998-11-17 University Of California Method for treating tumors
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
JP2000502711A (ja) * 1995-12-28 2000-03-07 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オブ メディシン 同種異系パラクリンサイトカイン腫瘍ワクチン
DE69721731T2 (de) * 1996-02-02 2004-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immortalisierte menschliche prostata-epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Similar Documents

Publication Publication Date Title
JP2012021028A5 (enExample)
CA2354046A1 (en) New cancer treatments
JP2002531521A5 (enExample)
ES2848064T3 (es) Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas
Zheng et al. Applications of bacillus Calmette–Guerin and recombinant bacillus Calmette–Guerin in vaccine development and tumor immunotherapy
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
JP2013536240A5 (enExample)
Johansen et al. New routes for allergen immunotherapy
JP2007524613A5 (enExample)
JP2015533376A5 (enExample)
JP2020528911A5 (enExample)
Xiang et al. Promising particle-based vaccines in cancer therapy
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
Yu et al. Therapeutic dendritic cell vaccines engineered with antigen‐biomineralized Bi2S3 nanoparticles for personalized tumor radioimmunotherapy
EP2385060A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
JP2014139185A5 (enExample)
Rong et al. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine
JP2015526469A5 (enExample)
JP2002531520A5 (enExample)
Domingos-Pereira et al. Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder
CA2354045A1 (en) New cancer treatments
RU2013143741A (ru) Терапевтическая вакцина против рака
AR097881A1 (es) FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO
CN115443333A (zh) 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
Johansen et al. Parenteral vaccine administration: tried and true